Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV : Insights from the Icona cohort
HIV Medicine · 2025
DOI: 10.1111/hiv.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Andrea De Vito und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Tenofovir, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme.
Abstract (Originalsprache)
Objectives
Most treatment switches are for simplification from three‐drug (3DR) to dual regimens (2DR). However, a proportion of people with HIV may switch back to 3DR, like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 2DR.
Methods
We included people with HIV enroled in the Icona cohort who switched to B/F/TAF after 2DR INSTI‐based (3TC/DTG, RPV/DTG, RPV/CAB, or DOR + DTG). Virological rebound (VR), virological suppression (VS), and treatment discontinuation (TD) due to toxicity or failure were evaluated using Kaplan–Meier curves. Random intercept and slopes before and after the switch were used to evaluate the trajectories of triglycerides, cholesterol, CD4, and CD4/CD8. Viro‐immunological analyses were stratified according to HIV‐RNA at switch.
Results
Among the 3662 people with HIV who started a 2DR INSTI‐based regimen, 71 (1.9%) switched to B/F/TAF; 60 had been followed up after the switch, for a median of 10.9 months (interquartile range: 3.6–24.7). Forty people with HIV switched with HIV‐RNA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Infectious Disease, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
- PhD School in Biomedical Science, Biomedical Science Department, University of Sassari, Sassari, Italy.
- ICONA Foundation, Milan, Italy.
- National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
- Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
- III Infectious Diseases Unit, ASST FBF-Sacco, Milan, Italy.
ORCID-Profile: Andrea De Vito, Alessandro Tavelli, Alessandro Cozzi-Lepri, Roberto Rossotti, Antonella d'Arminio Monforte
Förderung
- Gilead Sciences
- ViiV Healthcare
- Merck Sharp & Dohme
- Janssen-Cilag
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
De Vito, A., Tavelli, A., Cozzi-Lepri, A., Giacomelli, A., Rossotti, R., Ponta, G., Bobbio, N., Ianniello, A., Cingolani, A., Madeddu, G., Antinori, A., d'Arminio Monforte, A., & ICONA Foundation Study Group (2025). Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV : Insights from the Icona cohort. HIV Medicine. https://doi.org/10.1111/hiv.70037
Vancouver
De Vito A, Tavelli A, Cozzi-Lepri A, Giacomelli A, Rossotti R, Ponta G, et al. Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV : Insights from the Icona cohort. HIV Medicine. 2025. doi:10.1111/hiv.70037
BibTeX
@article{DeVito2025,
author = {De Vito, Andrea and Tavelli, Alessandro and Cozzi-Lepri, Alessandro and Giacomelli, Andrea and Rossotti, Roberto and Ponta, Giacomo and Bobbio, Nicoletta and Ianniello, Alice and Cingolani, Antonella and Madeddu, Giordano and Antinori, Andrea and d'Arminio Monforte, Antonella and ICONA Foundation Study Group, ICONA Foundation Study Group},
title = {Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV : Insights from the Icona cohort},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70037}
}
EUVIMED